Skip to content

About Avicanna

About Avicanna

About

Avicanna Is a Commercial-Stage International Biopharmaceutical Company Focused on the Advancement and Commercialization of Evidence-Based Cannabinoid-Based Products for the Global Medical and Pharmaceutical Market Segments
Founded in 2016 in Toronto, Canada. Avicanna has focused on the medical applications and potential of cannabinoids and has dedicated 8 years to R&D and clinical development of its proprietary products. Supported by its Canadian scientific platform, Avicanna has successfully commercialized its proprietary products into 19 international markets.

Market Segments

Serving the Global Marketplace with Proprietary Advanced Cannabinoid-Based Products

Four Commercial Stage Business Pillars

Avicanna’s scientific platform has resulted in 30+ commercial and proprietary formulations and products
Including medical cannabis, medical cannabis care, Pharmaceutical pipeline and active pharmaceutical ingredients

Medical Cannabis Care Platform

Medical Cannabis Products

Pharmaceutical Pipeline

Active Pharmaceutical Ingredients

1

Medical Cannabis & Wellness Products

Medical Cannabis Products and RHO Phyto

The portfolio contains a diverse range of advanced formulations including oral, sublingual, topical, and transdermal deliveries with varying ratios of cannabinoids such CBD, CBG and THC for international medical market segments.

The formulary is supported by ongoing patient, and medical community education and training including https://avicenna-academy.teachable.com/ 

The brand is currently available nationwide to patients in medical channels across Canada including MyMedi.ca launched August 2023. It is also accessible through several other medical institutions including The University Health Network (“UHN”) and the Odette Cancer Centre pharmacy of Sunnybrook Health Science Centre, a major hospital group in Canada. 

2

Pharmaceutical Pipeline

Pharmaceutical candidates designed to address 5 major clinical indications

Leveraging Avicanna’s scientific platform, vertical integration, and real-world evidence, Avicanna has developed a pipeline of indication-specific drug candidates that are in various stages of clinical development, registration, and commercialization.

These cannabinoid-based drug candidates are designed to address unmet medical needs in the areas of dermatology, chronic pain, and various neurological disorders.

3

MyMedi.ca- Medical Cannabis Care Platform

MyMedi.ca is a medical cannabis care platform formed with the aim to better serve medical cannabis patients’ needs and enhance the patient journey. MyMedi.ca is operated by Northern Green Canada Inc. under an agreement and features diverse portfolio of products and a pharmacist led patient support groups such as veterans and collaborating with public and private providers for adjudication and reimbursement and educational resources to facilitate the incorporation of medical cannabis into health care regimes.

4

Active Pharmaceutical Ingredients (Aureus Santa Marta™)

Aureus Santa Marta is a brand of active pharmaceutical ingredients (“API”) supplied by the Company’s majority owned subsidiary Santa Marta Golden Hemp SAS (“SMGH”) is a commercial-stage business dedicated to providing various forms high-quality CBD, THC and CBG to the Company’s international partners for use in the development and production of food, cosmetics, medical, and pharmaceutical products. The business unit also forms part of the Company’s supply chain and is a source of reliable input products for its consumer retail, medical cannabis, and pharmaceutical products globally.

Industry Leading Scientific Platform

Setting the Standard in the Cannabinoid Industry with Advanced and Evidence-Based Products

Scientific Platform

R&D Platform Delivering Advanced and Evidence-Based Cannabinoid Products

30+

Proprietary Commercial Products

10+

Scientists

11

Canadian Government Research Grants Awarded Since 2020

4

Health Canada Cannabis
Research Licenses to Avicanna
or Institutional Collaborators

Several issued and pending patents